65262
document
Association of PAX4 genetic variants with oral antidiabetic drugs efficacy in Chinese type 2 diabetes patients . The aim of this study was to investigate the association of PAX4 variants with therapeutic effect of oral antidiabetic drugs in Chinese type 2 diabtes mellitus ( T2DM ) patients . A total of 209 newly diagnosed T2DM patients were randomly assigned to treatment with repaglinide or rosiglitazone for 48 weeks , and the therapeutic effects were compared . In the rosiglitazone cohort , rs6467136 GA+AA carriers showed greater decrease in 2-h glucose levels ( P=0.0063 ) and higher cumulative attainment rates of target 2-h glucose levels ( Plog rank=0.0093 ) than GG homozygotes . In the subgroup with defective β-cell function , rs6467136 GA+AA carriers exhibited greater decrements of 2-h glucose level and improvement of homeostasis model assessment of insulin resistance ( P=0.0143 ) . Moreover , GA+AA carriers were more likely to attain the target fasting and 2-h glucose level ( Plog rank=0.0091 and 0.007 , respectively ) . However , these single-nucleotide polymorphisms showed no effect on repaglinide efficacy . In conclusion , PAX4 variant rs6467136 was associated with the therapeutic effect of rosiglitazone in Chinese T2DM patients .
65263
Intervention_Pharmacological
oral antidiabetic drugs
65264
Intervention_Pharmacological
oral antidiabetic drugs
65265
Intervention_Pharmacological
repaglinide
65266
Intervention_Pharmacological
rosiglitazone
65267
Intervention_Pharmacological
rosiglitazone
65268
Participant_Condition
Chinese type 2 diabetes patients
65269
Participant_Condition
PAX4 variants
65270
Participant_Condition
Chinese type 2 diabtes mellitus ( T2DM ) patients
65271
Participant_Sample-size
A total
65272
Participant_Sample-size
209
65273
Participant_Condition
in Chinese